Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Ribonucleases and their antitumor activity
Autore:
Matousek, J;
Indirizzi:
Acad Sci Czech Republ, Inst Anim Physiol & Genet, CR-27721 Libechov, CzechRepublic Acad Sci Czech Republ Libechov Czech Republic CR-27721 ov, CzechRepublic
Titolo Testata:
COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
fascicolo: 3, volume: 129, anno: 2001,
pagine: 175 - 191
SICI:
1532-0456(200107)129:3<175:RATAA>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
BOVINE SEMINAL RIBONUCLEASE; PLACENTAL ALKALINE-PHOSPHATASE; HUMAN PANCREATIC RIBONUCLEASE; DOUBLE-STRANDED-RNA; CATALYTIC ACTIVITY; TUMOR-GROWTH; IN-VITRO; P-30 PROTEIN; CELL-LINES; IMMUNOSUPPRESSIVE ACTIVITY;
Keywords:
angiogenin; antitumor; conjugation; enzyme; onconase; polymer; recombinant; ribonuclease; synthetic genes;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
143
Recensione:
Indirizzi per estratti:
Indirizzo: Matousek, J Acad Sci Czech Republ, Inst Anim Physiol & Genet, CR-27721 Libechov, CzechRepublic Acad Sci Czech Republ Libechov Czech Republic CR-27721 ublic
Citazione:
J. Matousek, "Ribonucleases and their antitumor activity", COMP BIOC C, 129(3), 2001, pp. 175-191

Abstract

The antitumor effect of ribonucleases was studied with animal ribonucleolytic enzymes, bovine pancreatic RNase A,bovine seminal RNase (BS-RNase), onconase and angiogenin. While bovine pancreatic RNase A exerts a minor antitumor effect, BS-RNase and onconase exert significant effects. Angiogenin, asRNase, works in an opposite way, it initiates vascularization of tumors and subsequent tumor growth. Ribonuclease inhibitors are not able to inhibit the antitumor effectiveness of BS-RNase or onconase. However, they do so inthe case of pancreatic RNases. Conjugation of BS-RNase with antibodies against tumor antigens (preparation of immunotoxins) like the conjugation of the enzyme with polymers enhances the antitumor activity of the ribonuclease. After conjugation with polymers, the half-life of BS-RNase in blood is extended and its immunogenicity reduced. Recombinant RNases have the same functional activity as the native enzymes. The synthetic genes have also been modified, some of them with gene sequences typical for the BS-RNase parts. Recent experimental efforts are directed to the preparation of 'humanized antitumor ribonuclease' that would be structurally similar to human enzyme with minimal immunogenicity and side effects. The angiogenesis of tumors is attempted to be minimized by specific antibodies or anti-angiogenic substances. (C) 2001 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/04/20 alle ore 12:19:24